Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.

Kim Hørslev-Petersen, Merete Lund Hetland, Peter Junker, Jan Pødenphanth, Torkell Ellingsen, Palle Ahlqvist, Hanne M. Lindegaard, Asta Linauskas, Annette Schlemmer, Mette Y. Dam, Ib Hansen, Hans Chr. Horn, Anette Jørgensen, Sophine Boysen Krintel, Johnny Raun, Christian G. Ammizbøll, Julia Sidenius Johansen, Mikkel Østergaard, Kristian Stengaard-Pedersen

    Abstract

    Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.
    OriginalsprogEngelsk
    TidsskriftArthritis & Rheumatism
    Vol/bind63
    Udgave nummer10 (suppl.)
    Sider (fra-til)S147
    Antal sider1
    ISSN0004-3591
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Adalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.'. Sammen danner de et unikt fingeraftryk.

    Citationsformater